Who
Steven C. Quay
President & CEO
Company insider
Files Form 4 as: President & CEO, Atossa Therapeutics; Chairman and CSO, Mdrna.
In numbers
- Trades disclosed
- 95
- Buys
- 4
- Sells
- 14
- Bought
- $33K
- Sold
- $981K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Feb 2006
- Last trade
- 27 Mar 2026
- Last filed
- 31 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Mar 2026filed 31 Mar 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 20 Jan 2026filed 30 Jan 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —331,674 at $0.00 | filing |
| 20 Jan 2026filed 30 Jan 2026 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $573K950,000 at $0.603 | filing |
| 20 Jan 2026filed 30 Jan 2026 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $570K950,000 at $0.60 | filing |
| 20 Jan 2026filed 30 Jan 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —331,674 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —325,203 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $573K950,000 at $0.603 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $570K950,000 at $0.60 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —325,203 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,89011,239 at $0.88 | filing |
| 15 May 2025filed 16 May 2025 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,366,062 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,795,100 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,873,100 at $0.00 | filing |
| 24 Feb 2022filed 28 Feb 2022 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,900,000 at $0.00 | filing |
| 14 May 2021filed 18 May 2021 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,900,000 at $0.00 | filing |
| 14 May 2021filed 18 May 2021 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,900,000 at $0.00 | filing |
| 9 Apr 2020filed 13 Apr 2020 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 9 Apr 2020filed 13 Apr 2020 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,305,000 at $0.00 | filing |
| 13 Jan 2019filed 15 Jan 2019 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,300,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.